In the Precision Medicine for Inflammatory Bowel Disease (IBD) project, we work to improve the diagnosis and treatment of IBD through new methods and technology. The project brings together a cross-sector group of partners from academia, healthcare providers, industry, and innovation actors and is led by the project coordinator RISE, with Innovation Skåne responsible for the group’s innovation environment.
Today, around 85,000 people in Sweden live with IBD, a chronic intestinal disease that includes Crohn’s disease and ulcerative colitis. Because the disease varies greatly between individuals, today’s general treatments are not always effective. By using precision medicine—where data about genes, gut bacteria, and disease patterns are analyzed—healthcare can be adapted to each patient.
The project’s goal is to create a dynamic innovation environment for precision medicine in IBD, where cutting-edge research meets healthcare providers and industry, resulting in accurate diagnostics and effective treatments through collaboration. The focus is on:
- Strengthening collaboration between healthcare, research, and companies to develop new treatment methods.
- Building long-term research environments where new models for IBD treatment can be tested.
- Improving diagnostics and treatment by predicting disease exacerbation and treatment responses.
- Developing AI-based decision support systems to help doctors provide the right treatment for each patient.
The project plays an important role in Swedish healthcare, where specialized centers for precision medicine within IBD are lacking.
Innovation Skåne leads and coordinates the work on the innovation environment, aiming to support the development and studies within the project while identifying new needs and building new collaborations based on them.
PROJECT IN BRIEF
Name: Precision Medicine for Inflammatory Bowel Disease
Time period: September 2024 – August 2027
Overall project goal: To establish an internationally recognized innovation environment that contributes to more accurate and effective care and treatment for individuals with IBD.
Funder: Vinnova
Coordinating project partner: RISE AB
Project partners: Innovation Skåne, AB Mavatar, Ersta Diakonisällskap Ersta Hospital, Lund University, Pfizer AB, Region Skåne, Region Östergötland, Takeda Pharma AB, Örebro University
